<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02853916</url>
  </required_header>
  <id_info>
    <org_study_id>B2016:51</org_study_id>
    <nct_id>NCT02853916</nct_id>
  </id_info>
  <brief_title>Efficacy of a Brown Seaweed Powder for Glycemic Control</brief_title>
  <official_title>Efficacy of a Brown Seaweed Powder for Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>innoVactiv Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manitoba</source>
  <brief_summary>
    <textblock>
      The objectives of this trial are to confirm efficacy in human of a brown seaweed powder and&#xD;
      explore dose-response relationship by comparing two different doses.&#xD;
&#xD;
      The primary endpoint is incremental area under the curve (iAUC, mmol*min/L) for blood&#xD;
      glucose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">October 25, 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incremental area under the curve (iAUC, mmol*min/L) of blood glucose</measure>
    <time_frame>0, 15, 30, 45, 60, 75, 90, 120, 150, 180 and 210 min</time_frame>
    <description>Incremental area under the curve (iAUC, mmol*min/L)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Blood Glucose</condition>
  <arm_group>
    <arm_group_label>500 mg InSea2®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>250 mg InSea2®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>500 mg InSea2®</intervention_name>
    <arm_group_label>500 mg InSea2®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>250 mg InSea2®</intervention_name>
    <arm_group_label>250 mg InSea2®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females aged between 18-45 y&#xD;
&#xD;
          -  Normoglycemic (fasting blood glucose &lt;5.6 mmol/L)&#xD;
&#xD;
          -  Body mass index (BMI) 18.5-29.9 kg/m2&#xD;
&#xD;
          -  Able to consume bread products&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Fasting blood glucose &gt; 5.6 mmol/L&#xD;
&#xD;
          -  Systolic blood pressure &gt; 140 mmHg and/or diastolic blood pressure &gt; 90 mmHg&#xD;
&#xD;
          -  Previous history of cardiovascular disease, diabetes, liver or kidney disease,&#xD;
             inflammatory bowel disease, celiac disease, short bowel syndrome, any malabsorptive&#xD;
             syndrome, pancreatitis, gallbladder or biliary disease&#xD;
&#xD;
          -  Presence of a gastrointestinal disorder within the past year&#xD;
&#xD;
          -  Presence of major gastrointestinal surgeries&#xD;
&#xD;
          -  Thyroid problems&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Consuming prescription or non-prescription drug, herbal or nutritional supplements&#xD;
             known to affect blood glucose or that could affect the outcome of the study as per&#xD;
             investigator's judgement&#xD;
&#xD;
          -  Women that are currently pregnant or lactating, or not using an appropriate&#xD;
             contraception method&#xD;
&#xD;
          -  Excessive alcohol intake (more than 2 drinks per day or more than 9 drinks per week)&#xD;
&#xD;
          -  Allergic to shellfish (crab) or molluscs&#xD;
&#xD;
          -  Weight gain or loss of at least 10lbs in previous three months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Jones, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Richardson Centre for Functional Foods and Nutraceuticals</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3T 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>July 14, 2016</study_first_submitted>
  <study_first_submitted_qc>July 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2016</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

